AstraZeneca cancer drug hits second goal by extending survival

LONDON (Reuters) - AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.

Third Indian state checks suspect cases in outbreak of rare brain-damaging virus

MUMBAI (Reuters) - Officials in a third Indian state were checking on Friday if two people had been infected with the brain-damaging Nipah virus that has killed 12 in southern Kerala, although the government described the outbreak as minor.

J&J must pay $4 million in punitive damages in latest asbestos cancer trial

(Reuters) - A California jury on Thursday ordered Johnson & Johnson to pay $4 million in punitive damages to a woman who said she developed cancer after being exposed to asbestos in the company's baby powder, pushing the total damages award in the case to $25.7 million.

FDA approves BioMarin rare metabolic disorder drug, shares rise

(Reuters) - U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.

Pressured by industry, U.S. EPA slows formaldehyde study release: documents

WASHINGTON (Reuters) - The U.S. Environmental Protection Agency, under pressure from the chemical industry, has delayed release of a study detailing cancer risks from formaldehyde, according to internal communications seen by Reuters, potentially keeping important health information from the public.

Infection alert after dying Ebola patients taken to Congo prayer meeting

GENEVA/KINSHASA (Reuters) - Two dying Ebola patients were spirited out of a Congo hospital by their relatives on motor-bikes, then taken to a prayer meeting with 50 other people, potentially exposing them all to the deadly virus, a senior aid worker said on Thursday.

Novartis receives EU approval for biosimilar Zessly

ZURICH (Reuters) - Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases.

Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

MELBOURNE (Reuters) - An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor.

Inogen's shares drop on short seller Citron's tweet

(Reuters) - Shares of Inogen Inc fell nearly 7 percent on Thursday after short seller Citron Research called the oxygen supply device maker the most expensive name in medical technology with no pipeline.

Oily fish still a good habit for heart health, U.S. doctors say

(Reuters Health) - People who eat at least two servings a week of oily fish like salmon, mackerel, herring and tuna should keep it up because U.S. doctors still say it's a good way to reduce the risk of heart attacks and strokes.

Related Videos

Aquatic moss that removes arsenic from water discovered

Hybrid-electric aircraft race heats up

You might like...

Check out our Reuters News Now daily briefing for hand-picked stories from Reuters editors. It's all the news you need to start your day.

Subscribe here